Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L1 protein is the major capsid protein of Human papillomavirus type 31 (HPV-31), a high-risk HPV associated with cervical and other anogenital cancers. L1 is essential for viral assembly, infectivity, and immunogenicity. Recombinant L1 can self-assemble into virus-like particles (VLPs) that closely mimic native virions but lack viral DNA, making them safe for vaccine use. L1 VLPs are used as antigens in prophylactic vaccines such as Gardasil 9. These vaccines induce neutralizing antibodies that prevent infection by blocking viral entry into host cells.
Neutralizing antibody induction via VLP formation
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus type 31 major capsid protein (L1).